Friday, February 13, 2009 6:47:10 AM
Diagnostic Testing & Technology Report
MacroArray Ready to Introduce Non-Invasive Prostate Cancer Test
April 2007
MacroArray Technologies (Philadelphia, PA) has developed a novel prostate cancer test that relies on the urine-based diagnostic marker known as PCADM-1 (for prostate cancer diagnostic marker 1), a 33 kDa chromosomal protein that is overexpressed in malignant prostate tissue. The marker was discovered by researchers at the Drexel University College of Medicine, with which MacroArray has a licensing agreement. Abbott Laboratories (Abbott Park, IL) will be the first to market the PCADM-1 urine test, after adapting the assay to its own platform.
Is this a confict of interest. Why has Abbott licensed this test also. Is this just another biomarker test to be used in conjunction with Hdvy's test. or a competing test. Just doing a late night word search on Abbott's endeavors and this came up. Any explainations appreciated in advance. Thanks
Recent HDVY News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 07:10:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:13:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 07:53:39 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM